Drug Discovery at Neurogeneration

Neurogeneration has established a highly-focused drug discovery platform built on the company’s deep knowledge of inhibitors and inflammatory events as causative factors of synaptic damages triggered by ABeta oligomers  accumulation. The company’s lead compound, NGN-9 is currently undergoing pharmacokinetic and hit identification studies. Neurogeneration selective novel small molecules therapy may become  a new treatment for […]

Read More Drug Discovery at Neurogeneration